

AMENDMENT

Please amend the claims as follows:

Please cancel claims 31, 41 and 47, without prejudice.

32. The expression vector of claim [31] 52 wherein said fusion immunoglobulin comprises a heavy chain and [has said] at least one [tolerogenic] epitope [inserted] positioned adjacent to the first framework region of the N-terminus variable region of [the] said heavy chain.

33. The vector of claim [31] 52 which is a retroviral vector.

34. The vector of claim [31] 52 wherein said antigen mediates [is associated with] an allergic reaction [and is] to an antigen selected from the group consisting of: pollen antigen, ragweed antigen, [or] and dust mite antigen.

35. The expression vector of claim [31] 52 wherein said antigen is an autoantigen and is selected from the group consisting of: clotting factor VIII, acetylcholine receptors, collagen, myelin basic protein, thyroglobulin, and histocompatibility antigen.

36. The expression vector of claim [31] 52 which contains more than one copy of the nucleotide sequence encoding said epitope.

37. The expression vector of claim [31] 52 wherein the fusion immunoglobulin is an IgG.

38. The expression vector of claim [31] 52 which has the characteristics of ATCC No. 69555.

39. A transformed haemopoietic or lymphoid cell comprising the expression vector of claim [31] 52.

42. The expression vector of claim [41] 53 wherein said antigen mediates [is associated with] autoimmune disease or allergic reactions [of] in said [animal] mammal.

44. The expression vector of claim 42 wherein said antigen is an autoantigen and is selected from the group consisting of: clotting factor VIII, acetylcholine receptors, collagen, myelin basic protein, thyroglobulin, and histocompatibility antigen.

45. The expression vector of claim [41] 53 which contains more than one copy of the nucleotide sequence encoding said epitope.

46. A transformed haemopoietic or lymphoid cell comprising the expression vector of claim [41] 53.

48. The expression vector of claim [47] 54 wherein said antigen is associated with autoimmune disease or allergic reactions of said [animal] mammal.

50. The expression vector of claim 48 wherein said antigen is an autoantigen and is selected from the group consisting of: clotting factor VIII antigen, acetylcholine receptors antigen, collagen antigen, myelin basic protein antigen, thyroglobulin antigen, and histocompatibility antigen.

51. A transformed haemopoietic or lymphoid cell comprising the expression vector of claim [41] 53.

Please add the following new claims:

--52. An expression vector comprising:

any promoter
a nucleotide sequence encoding a fusion immunoglobulin heavy or light chain operably linked to expression control regions that regulate the expression of said nucleotide sequence in a haemopoietic or lymphoid cell in a mammalian host;

wherein said fusion immunoglobulin comprises: an N-terminal variable region of said heavy or light chain; and wherein said N-terminal variable region further comprises at least one amino acid sequence that encodes a heterologous antigen epitope; and

wherein the expression on said vector in said haemopoietic or lymphoid cell of said nucleotide sequence induces immunological unresponsiveness to said antigen epitope in said mammalian host.

53. An expression vector comprising:

a nucleotide sequence encoding a fusion immunoglobulin heavy or light chain operably linked to expression control regions that regulate the expression of said nucleotide sequence in a haemopoietic or lymphoid cell in a mammalian host;

wherein said fusion immunoglobulin comprises: an N-terminal variable region of said heavy or light chain; and wherein said N-terminal variable region further comprises at least one amino acid sequence that encodes a heterologous antigen epitope; and

wherein the expression on said vector in said haemopoietic or lymphoid cell of said nucleotide sequence induces immunological unresponsiveness to said antigen epitope in said mammalian host; and wherein said vector is a retroviral vector.

54. An expression vector comprising:

a nucleotide sequence encoding a fusion immunoglobulin heavy or light chain operably linked to expression control regions that regulate the expression of said nucleotide sequence in a haemopoietic or lymphoid cell in a mammalian host;

wherein said fusion immunoglobulin comprises: an N-terminal variable region of said heavy or light chain; and wherein said N-terminal variable region further comprises at least one amino acid sequence that encodes a heterologous antigen epitope; and

wherein the expression on said vector in said haemopoietic or lymphoid cell of said nucleotide sequence induces immunological unresponsiveness to said antigen epitope in said mammalian host; and

wherein said vector contains more than one copy of the nucleotide sequence encoding said epitope.--

5

dc-184996

Serial N . 09/160,076
Docket No. 308072000110